.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Chinese Patent Office
Teva
Mallinckrodt
Federal Trade Commission
Covington
UBS
Deloitte
Cantor Fitzgerald
Julphar

Generated: June 25, 2017

DrugPatentWatch Database Preview

Claims for Patent: 4,983,598

« Back to Dashboard

Claims for Patent: 4,983,598

Title: Pharmaceutical composition containing diltiazem and angiotensin-converting enzyme inhibitor
Abstract:Compositions of diltiazem and angiotensin-converting enzyme inhibitor useful for the treatment of hypertension, cardiac insufficiency and coronary insufficiency.
Inventor(s): Cavero; Icilio (Creteil, FR), Elkik; Francois (Paris, FR), Hicks; Peter (Cachan, FR), Muller; Jean-Claude (Morsang S/Orge, FR)
Assignee: Synthelabo (Paris, FR)
Application Number:07/195,151
Patent Claims: 1. A pharmaceutical composition containing a combination of 10-360 mg of diltiazem and 1-100 mg of an angiotensin-converting enzyme inhibitor, enalapril useful for the treatment of hypertension, cardiac insufficiency, and coronary insufficiency, such that the anti-hypertensive effect observed upon combined administration of diltiazem and said angiotensin-converting enzyme inhibitor is greater than the sum of the individual anti-hypertensive effects observed upon the separate administration of diltiazem and said angiotensin-converting enzyme inhibitor alone.

2. A method for treatment of hypertension, cardiac insufficiency or coronary insufficiency comprising administering to a subject suffering therefrom a pharmaceutical composition containing a combination of 10 to 360 mg of diltiazem and 1 to 100 mg of an angiotensin-converting enzyme inhibitor, enalapril, such that the anti-hypertenive effect observed upon administration of the combined administration of diltiazem and said angiotensin-converting enzyme inhibitor is greater than the sum of the individual anti-hypertensive effects observed upon the separate administration of diltiazem and said angiotensin-converting enzyme inhibitor alone.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Dow
Healthtrust
Accenture
Chubb
Chinese Patent Office
Cantor Fitzgerald
Boehringer Ingelheim
McKinsey
Covington
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot